Fig. 1From: Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysisProgression-free survival (A) and overall survival (B). Group A was defined as patients treated with weekly low-dose administration of bevacizumab. Group B was defined as patients treated with monthly high-dose administration of bevacizumabBack to article page